Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man

What Was Tested

This randomized controlled trial paper looks at Angiotensin II and Bradykinin.

To investigate the interaction between angiotensin(1-7) Ang(1-7) and bradykinin in human forearm resistant vessels of normotensive healthy men in vivo, by the measurement of forearm blood flow using venous occlusion, strain-gauge plethysmography with intra-arterial infusions of peptides in a placebo-controlled, double-blind, cross-over design.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

In eight men, bradykinin was infused intra-arterially twice; placebo, Ang(1-7), or angiotensin II was co-infused with the second infusion.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

Some participants received a placebo instead of Angiotensin II, giving a reference point.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

The effect of inhibition of nitric oxide synthase on the interaction between Ang(1-7) and bradykinin was also tested in eight other individuals.

What Was Measured

PubMed files the paper under topics including Angiotensin I, Angiotensin II, Bradykinin, Drug Synergism, Enzyme Inhibitors, Peptide Fragments and Vasoconstrictor Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II and Bradykinin.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2001 (Journal of hypertension), a journal based in Netherlands.

More context: the Angiotensin II compound page and the Bradykinin compound page, all human trials.